Upregulation of SPINK2 in acute myeloid leukemia
Author:
Gezer Sümbül12, Emrence Zeliha1, Elverdi Tuğrul3, Ar Muhlis Cem3, Salman Yaylaz Burcu12, Paçal Ferda1, Ünüvar Ayşegül4, Sarıman Melda12, Eşkazan Ahmet Emre3ORCID, Karaman Serap4, Salihoğlu Ayşe3, Karakaş Zeynep4, Abacı Neslihan1, Sırma-Ekmekci Sema1ORCID
Affiliation:
1. Department of Genetics , Istanbul University, Aziz Sancar Institute of Experimental Medicine , Istanbul , Türkiye 2. Istanbul University, Institute of Graduate Studies in Health Sciences , Istanbul , Türkiye 3. Department of Internal Medicine , Cerrahpasa Faculty of Medicine, Division of Hematology, Istanbul University-Cerrahpasa , Istanbul , Türkiye 4. Division of Pediatric Hematology and Oncology , Istanbul University, Istanbul Faculty of Medicine , Istanbul , Türkiye
Abstract
Abstract
Objectives
Acute myeloid leukemia (AML) is a highly heterogeneous disease. Although patients can be classified into risk groups based on their genetic changes, the prognosis of disease within these categories varies widely. This situation raises the need to search for new molecular markers related to AML. Serine peptidase inhibitor Kazal type 2 (SPINK2) has recently been reported to be upregulated in AML and associated with poor outcomes by meta-analysis and in a limited number of AML patients.
Methods
We analyzed SPINK2 mRNA expression in 62 patients (45 adult and 17 pediatric) with AML and 11 cell lines using quantitative Real-Time PCR (qRT-PCR). SPINK2 protein level was determined using ELISA in cell lines.
Results
We found that the expression of SPINK2 mRNA and protein levels in AML cell lines (HL60 and NB4) have increased compared to other cell lines (K562, Jurkat and NALM6, MCF7, HeLa, HUVEC, hFOB, 293T, U87). SPINK2 mRNA expression was upregulated in patients with AML compared to controls (p=0.004) and significantly lower in t(8;21)-positive patients compared to negative patients (p=0.0006).
Conclusions
Our results suggest that SPINK2 serves an important role in AML development. Further studies are needed to evaluate SPINK2 expression in AML patients with t(8.21) and investigate to clarify its prognostic value in various subgroups of AML.
Funder
Scientific Research Projects Coordination Unit of Istanbul University
Publisher
Walter de Gruyter GmbH
Subject
Medical Laboratory Technology,Education,Medicine (miscellaneous)
Reference19 articles.
1. O’Reilly, E, Zeinabad, HA, Szegezdi, E. Hematopoietic versus leukemic stem cell quiescence: challenges and therapeutic opportunities. Blood Rev 2021;50:100850, https://doi.org/10.1016/j.blre.2021.100850. 2. Sill, H, Olipitz, W, Zebisch, A, Schulz, E, Wolfler, A. Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol 2011;162:792–805, https://doi.org/10.1111/j.1476-5381.2010.01100.x. 3. Arber, DA, Orazi, A, Hasserjian, R, Thiele, J, Borowitz, MJ, Le Beau, MM, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391–405, https://doi.org/10.1182/blood-2016-03-643544. 4. Shipley, JL, Butera, JN. Acute myelogenous leukemia. Exp Hematol 2009;37:649–58, https://doi.org/10.1016/j.exphem.2009.04.002. 5. Yu, J, Li, Y, Zhang, D, Wan, D, Jiang, Z. Clinical implications of recurrent gene mutations in acute myeloid leukemia. Exp Hematol Oncol 2020;9:4, https://doi.org/10.1186/s40164-020-00161-7.
|
|